Marvell Technology, Inc. R&D increased by 4.6% to $536.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 30.4%, from $411.20M to $536.00M. Over 4 years (FY 2022 to FY 2026), R&D shows an upward trend with a 17.0% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $286.10M | $367.00M | $371.90M | $83.00M | $444.10M | $449.00M | $448.10M | $347.70M | $480.70M | $474.80M | $481.10M | $444.80M | $476.10M | $486.70M | $488.60M | $411.20M | $507.70M | $519.00M | $512.50M | $536.00M |
| QoQ Change | — | +28.3% | +1.3% | -77.7% | +435.1% | +1.1% | -0.2% | -22.4% | +38.3% | -1.2% | +1.3% | -7.5% | +7.0% | +2.2% | +0.4% | -15.8% | +23.5% | +2.2% | -1.3% | +4.6% |
| YoY Change | — | — | — | — | +55.2% | +22.3% | +20.5% | +318.9% | +8.2% | +5.7% | +7.4% | +27.9% | -1.0% | +2.5% | +1.6% | -7.6% | +6.6% | +6.6% | +4.9% | +30.4% |